On-body delivery systems for subcutaneous isatuximab could enable patient self-administration, according to Xavier Leleu, MD, PhD, improving convenience and transforming treatment for relapsed/refractory multiple myeloma.
Xavier Leleu, MD, PhD
Advertisement
Xavier Leleu, MD, PhD, is the head of the Department of Haematology and the Myeloma Clinic at Hôpital La Mileterie, in Poitiers, France.
Articles by Xavier Leleu, MD, PhD
Trial Supports Subcutaneous Isatuximab as Effective Alternative to IV Version: Xavier Leleu, MD, PhD
The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma, according to Xavier Leleu, MD, PhD.
At the 30th European Hematology Association (EHA) Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide.
The phase 3 IRAKLIA trial assesses subcutaneous isatuximab via on-body injector vs intravenous (IV) administration, in combination with pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma (RRMM).
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Andes Hantavirus FAQs: What to Know as Quarantined Cruise Passengers Return Home
2
Rituximab Suppresses Clinical Relapses, MRI Activity in Pediatric MS
3
Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship
4
New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease
5